TXG
10x Genomics, Inc. Health Care Laboratory Analytical Instruments Russell 3000
$70.11Close
$9.0BMarket cap
$12.44 – $97.7452-week range
Nov 5, 2026Next report · after the close
Highlights
Strengths
- Leading the market RS 99 · stronger than 99% of stocks over 12 months
Cautions
- Trend not confirmed 6 of 8 conditions · under the 50-day, over 25% off the high
- Far from its high 28% below its 52-week high
- Earnings shrinking EPS −150% year on year
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
28%
1wk
down 2.0%
price change
1mo
down 22.4%
price change
12-month return
up 464%
market up 11% ·
its own up 433%
F-score
6 / 9
Mixed
Altman Z
20.93
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
11.2×
price / book
Earnings yield
down 0.7%
EBIT / enterprise value
Cheaper than
22%
of the market · expensive
Revenue growth
up 5%
year on year
EPS growth
down 150%
latest quarter
Sales growth
down 13%
latest quarter · -10 pts
ROE
down 6%
return on equity
Free cash margin
up 20%
$130.1M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- short-term liquidity weakened
- issued more shares
- generating cash from operations
- profitability improving
- profits backed by cash
- reduced long-term debt
- gross margin widened
- assets working harder
Repair signals
- FCF turned positive ($-6M → $130M)
- Gross margin 67.9% → 69.1%
- Revenue reaccelerating (-1% then +5%)
Trade setup
ATR%
9.9%
$6.92 a day · 2×ATR $56.27
RS
99 / 99
vs the universe
Trend
6 / 8
under the 50-day, over 25% off the high
Relative volume
1.5×
vs 50-day average
Up/down volume
1.31
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 6 of 8
- Price above the 50-day average: fails
- Within 25% of the 52-week high: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 4.4% over the year, from 122m to 128m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Last shock
Oct 6, 2026-17% in one session2.9× volumeno filing matched-13% since
Financials
- Gross 69%
- Net -7%
- Free cash 20%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $298.8M | $490.5M | $516.4M | $618.7M | $610.8M | $642.8M |
| Gross margin | 80% | 85% | 77% | 66% | 68% | 69% |
| Operating income | -$534.1M | -$52.3M | -$167.9M | -$265.3M | -$194.6M | -$61.0M |
| Net income | -$542.7M | -$58.2M | -$166.0M | -$255.1M | -$182.6M | -$43.5M |
| Net margin | -182% | -12% | -32% | -41% | -30% | -7% |
| Earnings per share | -$5.37 | -$0.53 | -$1.46 | -$2.18 | -$1.52 | -$0.35 |
| Free cash flow | -$254.6M | -$122.7M | -$165.3M | -$63.8M | -$5.7M | $130.1M |
| Free cash margin | -85% | -25% | -32% | -10% | -1% | 20% |
| Cash | $663.6M | $587.4M | $219.7M | $359.3M | $344.1M | $474.0M |
| Long-term debt | $0 | — | — | — | — | — |
| Shareholders' equity | $739.1M | $817.6M | $805.7M | $741.0M | $710.1M | $796.3M |
| Shares outstanding | 108.49m | 112.51m | 115.20m | 119.10m | 122.29m | 127.69m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 7, 2026 | Quarterly ↗ | Jun 30, 2026 | 38d |
| May 8, 2026 | Quarterly ↗ | Mar 31, 2026 | 38d |
| Feb 13, 2026 | Annual ↗ | Dec 31, 2025 | 44d |
| Nov 7, 2025 | Quarterly ↗ | Sep 30, 2025 | 38d |
| Aug 8, 2025 | Quarterly ↗ | Jun 30, 2025 | 39d |
| May 9, 2025 | Quarterly ↗ | Mar 31, 2025 | 39d |
| Feb 13, 2025 | Annual ↗ | Dec 31, 2024 | 44d |
| Oct 29, 2024 | Quarterly ↗ | Sep 30, 2024 | 29d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| Apr 30, 2024 | Quarterly ↗ | Mar 31, 2024 | 30d |
| Feb 15, 2024 | Annual ↗ | Dec 31, 2023 | 46d |
| Nov 3, 2023 | Quarterly ↗ | Sep 30, 2023 | 34d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 6, 2026 | Results ↗ |
| Jun 8, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Feb 12, 2026 | Results ↗ |
| Jan 12, 2026 | Results ↗ |
| Nov 14, 2025 | Director or officer change ↗ |
| Nov 6, 2025 | Results ↗ |
| Aug 7, 2025 | Results ↗ |
| Jun 5, 2025 | Shareholder vote ↗ |
| May 14, 2025 | Other events ↗ |
| May 8, 2025 | Results · Restructuring ↗ |
| Feb 12, 2025 | Results ↗ |